FDA
-
-
-
-
-
-
-
Cue Biopharma appoints new CEO, raises $30 million in first quarter
-
-
-
-
-
-
-
Cue Biopharma Announces 1-for-30 Reverse Stock Split
-
-
-
-
-
-
-
Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026
-
-
-
-
-
-
-
Cue Biopharma partners with ImmunoScape on solid tumor cell therapy
-
-
-
-
-
-
-
Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer
-
-
-
-
-
-
-
Boehringer Ingelheim and Cue Biopharma (CUE) partner to develop next-generation treatment for autoimmune and inflammatory diseases
-
-
-
-
-
-
-
Cue Biopharma Inc. (CUE) Appoints Lucinda Warren as Chief Business Officer
-
327,801 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

